Retatrutide vs tirzepatide for obesity (TRIUMPH-5)

Retatrutide (triple GIP/GLP-1/glucagon agonist) showed ~24% weight loss at 48 weeks in Phase 2, substantially exceeding tirzepatide's ~20-22% at 72 weeks in SURMOUNT. Head-to-head at 80 weeks strongly favors reta on superiority for % body weight change. Large Lilly Phase 3 program, well-powered, validated endpoint, prior class success. Main risk is operational/disclosure timing by 2027, not efficacy failure.

Phase 3, active-not-recruiting status and an objective Week 80 weight endpoint support execution and interpretable results. However, this is an active-comparator trial against tirzepatide, and no sample size, statistical margin or prior efficacy data are provided, limiting confidence and raising endpoint and disclosure risk.

Large Phase 3 active-comparator design with an objective, clinically meaningful Week 80 weight-loss endpoint. Retatrutide’s differentiated multi-agonist mechanism and prior substantial weight-loss signal support superiority potential, though tirzepatide is a strong comparator and long-duration tolerability, dose selection, and discontinuations could narrow the advantage.

Phase 3 status, an objective body-weight endpoint at Week 80, and a defined active comparator support a meaningful chance of success. However, the head-to-head design raises the efficacy bar, while effect-size assumptions, statistical margins, sample size, safety balance, and prior results are not provided, leaving material outcome uncertainty.

Phase 3 head-to-head by Lilly, active not recruiting, primary endpoint percent weight change at wk 80 vs active comparator tirzepatide; no safety or operational red flags in fields, standard design for next-gen asset implies likely superiority or clear positive readout.

Retatrutide, a triple GIP/GLP-1/glucagon receptor agonist, has demonstrated ~28% weight reduction in Phase 3 trials vs tirzepatide's historical ~22.5%. Glucagon agonism drives increased energy expenditure, providing a strong mechanistic advantage. With ~800 patients, the trial is vastly powered to show superiority on the primary endpoint of weight change at week 80.

Phase‑3 trial of Lilly's retatrutide vs tirzepatide in obese adults. Retatrutide showed ~15‑20% weight loss in Phase‑2, surpassing tirzepatide (~10%). Large sample, clear endpoint at week 80, low operational risk, and sponsor's strong track record suggest a >50% chance of meeting superiority. Disclosure risk low.

Retatrutide Phase 2 showed ~24% weight loss at 48 weeks vs tirzepatide's ~20% in SURMOUNT. Triple agonist (GIP/GLP-1/glucagon) mechanism is more potent. Phase 3 head-to-head superiority design with 80-week endpoint is well-suited. Active not recruiting status suggests enrollment complete and execution on track. Main risks: GI tolerability at higher doses and tirzepatide being a strong comparator, but Phase 2 superiority signal is robust.